Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome

Página do item simplificado
dc.contributor.authorMello, Valderez Raposo de
dc.contributor.authorRodrigues, Maira Tinte
dc.contributor.authorMastrocinque, Tais Helena
dc.contributor.authorLaranjo Martins, Simone Paiva
dc.contributor.authorBraga de Andrade, Olberes Vitor
dc.contributor.authorMedeiros Guidoni, Eliana Biondi
dc.contributor.authorScheffer, Daniel Kashiwamura
dc.contributor.authorMartini Filho, Dino
dc.contributor.authorToporovski, Julio
dc.contributor.authorBenini, Vanda
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionSanta Casa São Paulo
dc.date.accessioned2016-01-24T13:59:23Z
dc.date.available2016-01-24T13:59:23Z
dc.date.issued2010-03-01
dc.description.abstractThe purpose of this study was to assess the results of therapy with mycophenolate mofetil (MMF) in children with idiopathic nephrotic syndrome (INS) who were both steroid- and cyclophosphamide-resistant. Treatment lasted a minimum of 6 months, and follow-up data were collected over a 2-year period. the children were divided into two groups: Group 1 (n = 34) comprised patients who had received cyclosporine A (CsA) before the initiation of MMF therapy; Group 2 (n = 18) comprised patients who received only MMF. Among the 34 patients of Group 1, complete and partial remission were achieved in seven (20.6%) and 13 patients (38.6%), respectively; there was no response in 14 patients (41.2%). Among the 18 patients in Group 2, complete and partial remission occurred in five (27.8%) and six (33.3%) patients, respectively; there was no response in seven patients (38.9%). Eight patients developed chronic kidney disease. the main side-effects were gastrointestinal complaints (n = 11, 21%), recurring severe infections (n = 1, 1.9%), and mild thrombocytopenia/leucopenia (n = 1, 1.9%). MMF proved to be therapeutically effective in 59.5% of the cases. These beneficial effects need to be confirmed in studies with a long-term follow-up after discontinuation of the treatment. Our statistical analysis of the results of therapy with MMF did not reveal any significant difference between its use alone or following CsA administration.en
dc.description.affiliationSanta Casa São Paulo, Dept Pediat, Div Pediat Nephrol, BR-05435000 São Paulo, Brazil
dc.description.affiliationSanta Casa São Paulo, Dept Social Med, BR-01221020 São Paulo, Brazil
dc.description.affiliationSanta Casa São Paulo, Dept Pathol, BR-01221020 São Paulo, Brazil
dc.description.affiliationSanta Casa São Paulo, Dept Pediat, Div Pediat Nephrol, BR-01221020 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent453-460
dc.identifierhttp://dx.doi.org/10.1007/s00467-009-1356-x
dc.identifier.citationPediatric Nephrology. New York: Springer, v. 25, n. 3, p. 453-460, 2010.
dc.identifier.doi10.1007/s00467-009-1356-x
dc.identifier.issn0931-041X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/32319
dc.identifier.wosWOS:000273950600008
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofPediatric Nephrology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectCyclophosphamide resistanten
dc.subjectCyclosporine Aen
dc.subjectGlomerulopathiesen
dc.subjectGlomerulosclerosisen
dc.subjectMycophenolate mofetilen
dc.subjectNephrotic syndromeen
dc.subjectSteroid resistanten
dc.titleMycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndromeen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral